Recently, the product "Carbon Ion Therapy System" produced by Lanzhou Ion Therapy Co. Ltd. is approved by China NMPA.

The approved product will be put into clinical use at Economic and Technological Development Zone Branch, Renmin Hospital of Wuhan University. Compared with previously approved products, all treatment rooms in this system are equipped with modulated scanning mode, which further enhances treatment efficiency and precision. Some treatment rooms are also configured with a sliding rail CT image guidance system, improving image quality and positioning accuracy, thus better meeting the needs of patients with malignant solid tumors.

In recent years, the NMPA has continuously deepened its review and approval reforms, supporting innovation in the medical device industry and meeting the public's demand for high-end medical devices. Previously, the domestically produced "Carbon Ion Therapy System" approved by the NMPA has been used to treat over 1,500 patients, with excellent outcomes.

Moving forward, the NMPA will continue to implement specific measures in line with the reform deployments of the Central Committee of the Communist Party of China, supporting the high-quality development of the medical device industry. For innovative products, the NMPA will adopt an approach of "early intervention, tailored strategies for each enterprise, full-process guidance, and integrated research and review" to accelerate their market entry, better protect and promote public health, and propel China's transformation from a big pharmaceutical manufacturing country to a powerful one.